Clin Exp Vaccine Res.  2017 Jan;6(1):22-30. 10.7774/cevr.2017.6.1.22.

Tetanus–diphtheria–acellular pertussis vaccination for adults: an update

• Lee HJ
• Choi JH

• KMID: 2366888
• DOI: http://doi.org/10.7774/cevr.2017.6.1.22

Abstract

Although tetanus and diphtheria have become rare in developed countries, pertussis is still endemic in some developed countries. These are vaccine-preventable diseases and vaccination for adults is important to prevent the outbreak of disease. Strategies for tetanus, diphtheria, and pertussis vaccines vary from country to country. Each country needs to monitor consistently epidemiology of the diseases and changes vaccination policies accordingly. Recent studies showed that tetanus-diphtheria-acellular pertussis vaccine for adults is effective and safe to prevent pertussis disease in infants. However, vaccine coverage still remains low than expected and seroprevalence of protective antibodies levels for tetanus, diphtheria, and pertussis decline with aging. The importance of tetanus-diphtheria-acellular pertussis vaccine administration should be emphasized for the protection of young adult and elderly people also, not limited to children.

Keyword

Whooping cough; Diphtheria; Tetanus; Diphtheria-tetanus-acellular pertussis vaccines; Adult

MeSH Terms

Adult*
Aged
Aging
Antibodies
Child
Developed Countries
Diphtheria
Diphtheria-Tetanus-acellular Pertussis Vaccines
Epidemiology
Humans
Infant
Pertussis Vaccine
Seroepidemiologic Studies
Tetanus
Vaccination*
Vaccines
Whooping Cough*
Young Adult
Antibodies
Diphtheria-Tetanus-acellular Pertussis Vaccines
Pertussis Vaccine
Vaccines

Reference

1. Weinberger B. Adult vaccination against tetanus and diphtheria: the European perspective. Clin Exp Immunol. 2017; 187:93–99.

2. Swanson KA, Schmitt HJ, Jansen KU, Anderson AS. Adult vaccination. Hum Vaccin Immunother. 2015; 11:150–155.

3. Gautret P, Wilder-Smith A. Vaccination against tetanus, diphtheria, pertussis and poliomyelitis in adult travellers. Travel Med Infect Dis. 2010; 8:155–160.

4. Hamborsky J, Kroeger A, Wolfe S. Epidemiology and prevention of vaccine-preventable diseases. 13th ed. Washington, DC: Centers for Disease Control and Prevention;2015.

5. Trucchi C, Zoppi G. Decennial diphtheria-tetanus adult boosters: are they really necessary? J Prev Med Hyg. 2015; 56:E44–E48.

6. Mattos-Guaraldi AL, Moreira LO, Damasco PV, Hirata Junior R. Diphtheria remains a threat to health in the developing world: an overview. Mem Inst Oswaldo Cruz. 2003; 98:987–993.

7. Sartori AM, de Soarez PC, Fernandes EG, Gryninger LC, Viscondi JY, Novaes HM. Cost-effectiveness analysis of universal maternal immunization with tetanus-diphtheria-acellular pertussis (Tdap) vaccine in Brazil. Vaccine. 2016; 34:1531–1539.

8. Maertens K, Cabore RN, Huygen K, Hens N, Van Damme P, Leuridan E. Pertussis vaccination during pregnancy in Belgium: results of a prospective controlled cohort study. Vaccine. 2016; 34:142–150.

9. Suryadevara M, Domachowske JB. Prevention of pertussis through adult vaccination. Hum Vaccin Immunother. 2015; 11:1744–1747.

10. Lu PJ, O'Halloran A, Ding H, Liang JL, Williams WW. National and state-specific Td and Tdap vaccination of adult populations. Am J Prev Med. 2016; 50:616–626.

11. McCormack PL. Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix(R)): a review of its properties and use as a single-dose booster immunization. Drugs. 2012; 72:1765–1791.

12. Pichichero ME, Casey JR. Acellular pertussis vaccines for adolescents. Pediatr Infect Dis J. 2005; 24:6 Suppl. S117–S126.

13. Centers for Disease Control and Prevention (CDC). FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. MMWR Morb Mortal Wkly Rep. 2011; 60:1279–1280.

14. Kretsinger K, Broder KR, Cortese MM, et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep. 2006; 55:1–37.

15. Notifiable diseases and mortality tables. MMWR Morb Mortal Wkly Rep. 2016; 65:ND-38.

16. World Health Organization. WHO vaccine-preventable diseases: monitoring system: 2016 global summary [Internet]. Geneva: World Health Organization;2016. cited 2016 Nov 28. Available from: http://apps.who.int/immunization_monitoring/globalsummary.

17. National Advisory Committee on Immunization. Prevention of pertussis in adolescents and adults. Can Commun Dis Rep. 2003; 29:1–9.

18. European Centre for Disease Prevention and Control. Vaccine schedule [Internet]. European Centre for Disease Prevention and Control;2016. cited 2016 Nov 28. Available from: http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx.

19. Beard FH. Pertussis immunisation in pregnancy: a summary of funded Australian state and territory programs. Commun Dis Intell Q Rep. 2015; 39:E329–E336.

20. Srivastava RK. Adult immunization. Delhi: National Centre for Disease Control;2011.

21. Wu LA, Kanitz E, Crumly J, D'Ancona F, Strikas RA. Adult immunization policies in advanced economies: vaccination recommendations, financing, and vaccination coverage. Int J Public Health. 2013; 58:865–874.

22. Okada K, Ueda K, Morokuma K, Kino Y, Tokugawa K, Nishima S. Seroepidemiologic study on pertussis, diphtheria, and tetanus in the Fukuoka area of southern Japan: seroprevalence among persons 0-80 years old and vaccination program. Jpn J Infect Dis. 2004; 57:67–71.

23. Nakayama T. Vaccine chronicle in Japan. J Infect Chemother. 2013; 19:787–798.

24. Li X, Chen M, Zhang T, Li J, Zeng Y, Lu L. Seroepidemiology of diphtheria and pertussis in Beijing, China: a cross-sectional study. Hum Vaccin Immunother. 2015; 11:2434–2439.

25. Choi WS, Choi JH, Kwon KT, et al. Revised adult immunization guideline recommended by the korean society of infectious diseases, 2014. Infect Chemother. 2015; 47:68–79.

26. Collins S, Amirthalingam G, Beeching NJ, et al. Current epidemiology of tetanus in England, 2001-2014. Epidemiol Infect. 2016; 144:3343–3353.

27. Zielinski A, Rudowska J. Tetanus in Poland in 2013. Przegl Epidemiol. 2015; 69:263–265. 379–380.

28. Filia A, Bella A, von Hunolstein C, et al. Tetanus in Italy 2001-2010: a continuing threat in older adults. Vaccine. 2014; 32:639–644.

29. Quinn HE, McIntyre PB. Tetanus in the elderly: an important preventable disease in Australia. Vaccine. 2007; 25:1304–1309.

30. Harding HE, Cawich SO, Williams EW, Crandon IW, Williams-Johnson J. Epidemiology of tetanus in Jamaica, 1993-2010. Trop Doct. 2014; 44:166–168.

31. Amare A, Melkamu Y, Mekonnen D. Tetanus in adults: clinical presentation, treatment and predictors of mortality in a tertiary hospital in Ethiopia. J Neurol Sci. 2012; 317:62–65.

32. Anuradha S. Tetanus in adults: a continuing problem: an analysis of 217 patients over 3 years from Delhi, India, with special emphasis on predictors of mortality. Med J Malaysia. 2006; 61:7–14.

33. Sadoh AE, Oladokun RE. Re-emergence of diphtheria and pertussis: implications for Nigeria. Vaccine. 2012; 30:7221–7228.

34. Wanlapakorn N, Yoocharoen P, Tharmaphornpilas P, Theamboonlers A, Poovorawan Y. Diphtheria outbreak in Thailand, 2012; seroprevalence of diphtheria antibodies among Thai adults and its implications for immunization programs. Southeast Asian J Trop Med Public Health. 2014; 45:1132–1141.

35. World Health Organization. Summary of WHO position papers: recommendations for routine immunization [Internet]. Geneva: World Health Organization;2016. cited 2016 Nov 28. Available from: http://www.who.int/immunization/documents/positionpapers/en/.

36. Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women: Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep. 2013; 62:131–135.

37. Vilajeliu A, Gonce A, Lopez M, et al. Combined tetanus-diphtheria and pertussis vaccine during pregnancy: transfer of maternal pertussis antibodies to the newborn. Vaccine. 2015; 33:1056–1062.

38. Weston W, Messier M, Friedland LR, Wu X, Howe B. Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine. Vaccine. 2011; 29:8483–8486.

39. Tomovici A, Barreto L, Zickler P, et al. Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. Vaccine. 2012; 30:2647–2653.

40. Healy CM, Rench MA, Baker CJ. Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (Tdap) immunization and protection of young infants. Clin Infect Dis. 2013; 56:539–544.

41. Englund JA. The influence of maternal immunization on infant immune responses. J Comp Pathol. 2007; 137:Suppl 1. S16–S19.

42. Halperin BA, Morris A, Mackinnon-Cameron D, et al. Kinetics of the antibody response to tetanus-diphtheria-acellular pertussis vaccine in women of childbearing age and postpartum women. Clin Infect Dis. 2011; 53:885–892.

43. Winter K, Nickell S, Powell M, Harriman K. Effectiveness of prenatal versus postpartum tetanus, diphtheria, and acellular pertussis vaccination in preventing infant pertussis. Clin Infect Dis. 2017; 64:3–8.

44. Castagnini LA, Healy CM, Rench MA, Wootton SH, Munoz FM, Baker CJ. Impact of maternal postpartum tetanus and diphtheria toxoids and acellular pertussis immunization on infant pertussis infection. Clin Infect Dis. 2012; 54:78–84.

45. Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older: Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep. 2012; 61:468–470.

46. Yorkgitis BK, Timoney G, Salim A, et al. Pertussis vaccination in adult trauma patients: are we missing an opportunity? Surgery. 2015; 158:602–607.

47. Kharbanda EO, Vazquez-Benitez G, Lipkind HS, et al. Maternal Tdap vaccination: coverage and acute safety outcomes in the vaccine safety datalink, 2007-2013. Vaccine. 2016; 34:968–973.

48. Kanitz EE, Wu LA, Giambi C, et al. Variation in adult vaccination policies across Europe: an overview from VENICE network on vaccine recommendations, funding and coverage. Vaccine. 2012; 30:5222–5228.

49. Lee SY, Han SB, Bae EY, et al. Pertussis seroprevalence in Korean adolescents and adults using anti-pertussis toxin immunoglobulin G. J Korean Med Sci. 2014; 29:652–656.

50. Wanlapakorn N, Ngaovithunvong V, Thongmee T, Vichaiwattana P, Vongpunsawad S, Poovorawan Y. Seroprevalence of antibodies to pertussis toxin among different age groups in Thailand after 37 years of universal whole-cell pertussis vaccination. PLoS One. 2016; 11:e0148338.

51. Swart EM, van Gageldonk PG, de Melker HE, van der Klis FR, Berbers GA, Mollema L. Long-term protection against diphtheria in the Netherlands after 50 years of vaccination: results from a seroepidemiological study. PLoS One. 2016; 11:e0148605.

52. Sung H, Jang MJ, Bae EY, et al. Seroepidemiology of tetanus in Korean adults and adolescents in 2012. J Infect Chemother. 2014; 20:397–400.

53. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med. 2007; 357:1903–1915.

54. Terranella A, Rea V, Griffith M, et al. Vaccine effectiveness of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine during a pertussis outbreak in Maine. Vaccine. 2016; 34:2496–2500.

55. Klein NP, Bartlett J, Fireman B, Baxter R. Waning Tdap effectiveness in adolescents. Pediatrics. 2016; 137:e20153326.

56. Quinn HE, Snelling TL, Habig A, Chiu C, Spokes PJ, McIntyre PB. Parental Tdap boosters and infant pertussis: a case-control study. Pediatrics. 2014; 134:713–720.

57. Blain AE, Lewis M, Banerjee E, et al. An assessment of the cocooning strategy for preventing infant pertussis: United States, 2011. Clin Infect Dis. 2016; 63:Suppl 4. S221–S226.

58. van Wijhe M, McDonald SA, de Melker HE, Postma MJ, Wallinga J. Effect of vaccination programmes on mortality burden among children and young adults in the Netherlands during the 20th century: a historical analysis. Lancet Infect Dis. 2016; 16:592–598.

59. Baxter R, Lewis E, Goddard K, et al. Acute demyelinating events following vaccines: a case-centered analysis. Clin Infect Dis. 2016; 63:1456–1462.

60. Halperin SA, Sweet L, Baxendale D, et al. How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine? Pediatr Infect Dis J. 2006; 25:195–200.

61. Jackson LA, Yu O, Belongia EA, et al. Frequency of medically attended adverse events following tetanus and diphtheria toxoid vaccine in adolescents and young adults: a Vaccine Safety Datalink study. BMC Infect Dis. 2009; 9:165.

62. Talbot EA, Brown KH, Kirkland KB, Baughman AL, Halperin SA, Broder KR. The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak. Vaccine. 2010; 28:8001–8007.

63. Sukumaran L, McCarthy NL, Kharbanda EO, et al. Association of Tdap vaccination with acute events and adverse birth outcomes among pregnant women with prior tetanus-containing immunizations. JAMA. 2015; 314:1581–1587.

64. Walls T, Graham P, Petousis-Harris H, Hill L, Austin N. Infant outcomes after exposure to Tdap vaccine in pregnancy: an observational study. BMJ Open. 2016; 6:e009536.

65. Moro PL, Cragan J, Tepper N, et al. Enhanced surveillance of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccines in pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 2011-2015. Vaccine. 2016; 34:2349–2353.

66. Datwani H, Moro PL, Harrington T, Broder KR. Chorioamnionitis following vaccination in the vaccine adverse event reporting system. Vaccine. 2015; 33:3110–3113.

67. Moro PL, McNeil MM, Sukumaran L, Broder KR. The Centers for Disease Control and Prevention’s public health response to monitoring Tdap safety in pregnant women in the United States. Hum Vaccin Immunother. 2015; 11:2872–2879.